Financial health
- The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $0 | -$8M | — | — | -919.3% | -241.1% | -$7M | — | $2M |
| 2024 | $58000 | -$8M | 0.0% | -13794.8% | -949.3% | -213.4% | -$8M | — | $2M |
| 2023 | $477000 | -$12M | 0.0% | -2441.1% | 721.8% | -387.4% | -$10M | — | $1M |
| 2022 | $1M | -$12M | 0.0% | -880.3% | -243.4% | -121.6% | -$11M | — | $7M |
| 2021 | $1M | -$13M | 100.0% | -1244.3% | -121.7% | -80.3% | -$10M | — | $13M |
| 2020 | $145000 | -$15M | 97.2% | -10709.7% | -78.2% | -64.1% | -$12M | — | $21M |
| 2019 | $710000 | -$15M | 49.6% | -2001.8% | -620.6% | -191.6% | -$10M | — | $6M |
| 2018 | $625000 | -$14M | 17.3% | -2256.3% | -368.9% | -218.0% | -$11M | — | $5M |
| 2017 | $479000 | -$12M | -44.1% | -2589.8% | -110.6% | -90.9% | -$9M | — | $13M |
| 2016 | $576000 | -$10M | -29.5% | -1320.8% | -50.1% | -46.7% | — | — | $21M |
| 2015 | — | -$7M | — | — | 194.6% | -137.7% | -$7M | — | $4M |
| 2014 | — | $234000 | — | — | -0.5% | 1.7% | — | — | $3M |
| 2014 | — | $83000 | — | — | 0.6% | 0.6% | — | — | $13M |
| 2013 | — | $19000 | — | — | 0.1% | 0.1% | — | — | $13M |
| 2012 | — | $305000 | — | — | 2.3% | 2.3% | -$310000 | — | $13M |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | — | -$2M | — | — | -59.7% | -33.9% | -$2M | — | $4M |
| Mar '26 | — | -$2M | — | — | 211.9% | -132.0% | -$2M | — | $951000 |
| Dec '25 | $0 | -$2M | — | — | -221.7% | -58.1% | -$3M | — | $2M |
| Sep '25 | $0 | -$1M | — | — | -56.5% | -24.1% | -$2M | — | $5M |
| Jun '25 | $0 | -$2M | — | — | 108.6% | -98.1% | -$2M | — | $980000 |
| Mar '25 | $0 | -$3M | — | — | 178.4% | -125.2% | -$2M | — | $949000 |
| Dec '24 | $0 | -$2M | — | — | -274.3% | -61.7% | -$2M | — | $2M |
| Sep '24 | $0 | -$2M | — | — | -63.1% | -27.7% | -$3M | — | $5M |
| Jun '24 | $3000 | -$2M | 0.0% | -54966.7% | 83.9% | -57.0% | -$1M | — | $1M |
| Mar '24 | $55000 | -$2M | 0.0% | -4136.4% | 99.6% | -84.6% | -$2M | — | $949000 |
| Dec '23 | $13000 | -$2M | 0.0% | -16030.8% | 129.3% | -69.4% | -$2M | — | $1M |
| Sep '23 | $357000 | -$3M | 0.0% | -727.7% | 390.0% | -68.7% | -$2M | — | $2M |
| Jun '23 | $43000 | -$3M | 0.0% | -8027.9% | -209.4% | -53.6% | -$3M | — | $4M |
| Mar '23 | $64000 | -$4M | 0.0% | -5484.4% | -184.3% | -49.1% | -$3M | — | $5M |
| Dec '22 | $106000 | -$3M | 0.0% | -2847.2% | -61.9% | -30.9% | -$3M | — | $7M |
| Sep '22 | $212000 | -$3M | 0.0% | -1443.4% | -74.6% | -33.3% | -$2M | — | $7M |
| Jun '22 | $974000 | -$2M | 0.0% | -256.3% | -37.1% | -22.2% | -$3M | — | $9M |
| Mar '22 | $60000 | -$3M | 0.0% | -5545.0% | -45.1% | -25.9% | -$3M | — | $7M |
| Dec '21 | $79000 | -$3M | 100.0% | -4381.0% | -33.4% | -22.0% | -$3M | — | $13M |
| Sep '21 | $821000 | -$3M | 100.0% | -329.8% | -20.2% | -15.6% | -$3M | — | $16M |
How the market has priced BCDA against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
See the revenue and net-income charts above for BioCardia, Inc.'s multi-year trend.
As of FY2025, BioCardia, Inc. reported — of total debt against $2M of cash.
In FY2025, gross margin was —, operating margin —, and net margin —.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.